Researcher urges Health Canada to suspend "unethical" diabetes drug trial

Eggertson, Laura
July 2010
CMAJ: Canadian Medical Association Journal;7/13/2010, Vol. 182 Issue 10, pE445
Academic Journal
The article reports on the initiative of Canadian medical researchers which urge Health Canada to suspend the unethical trial for type 2 diabetes drug rosiglitazone. It relates that a safety alert has been issued by the U.S. Food and Drug Administration in 2007 concerning the possible association of the diabetes drug to the increased risk of heart problems. It adds that the agency has ordered the drug maker GlaxoSmithKline to conduct a clinical trial in 2009.


Related Articles

  • FDA puts hold on rosiglitazone global post-marketing trial. Cohen, Deborah // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;7/31/2010, Vol. 341 Issue 7766, p222 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to suspend a post-marketing trial of thiazolidinedione rosiglitazone. FDA issued a partial clinical hold on a trial designed to compare the cardiovascular safety of rosiglitazone and pioglitazone in patients with...

  • FDA Panel: Keep Avandia on Market With Restrictions. Young, Donna // BioWorld Today;7/15/2010, Vol. 21 Issue 135, p1 

    The article reports on the decision of a U.S. Food and Drug Administration (FDA) panel to restrict the use of the Type II diabetes drug Avandia (rosiglitazone) in the U.S. market. The panel also warned on possible heart attacks among patients taking the drug, which is manufactured by...

  • FDA advisers recommend new controls on rosiglitazone use. Traynor, Kate // American Journal of Health-System Pharmacy;8/15/2010, Vol. 67 Issue 16, p1306 

    The article reports on the recommendation of U.S. Food and Drug Administration (FDA) advisers to control or totally ban the rosiglitazone in patients suffering from type 2 diabetes mellitus. It states that some advisers at the meeting held in Gaithersburg, Maryland on July 13-14, 2010 advised...

  • FDA committee urges tight restrictions on rosiglitazone. Roehr, Bob // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;7/24/2010, Vol. 341 Issue 7765, p171 

    The article reports on the recommendation to prohibit the use of rosiglitazone drug in treating type 2 diabetes by the U.S. Food and Drug Administration's (FDA) advisory committee.

  • The heartbreaking story of Avandia. Safyan, Susan // Alive: Canada's Natural Health & Wellness Magazine;Oct2007, Issue 300, p64 

    The article reports on the cardiovascular risk of Avandia, a drug for Type 2 Diabetes. Food and Drug Administration's (FDA) Office of Surveillance and Epidemiology (OSE) in the U.S. suggest to the health panelist the immediate withdrawal of the drug from the market after their thorough...

  • Regulatory Roundup.  // BioWorld Today;3/17/2009, Vol. 20 Issue 50, p3 

    The article announces investigational new drug approval for Melior Discovery Incorporated's novel diabetes drug MLR-1023. The Exton, Pennsylvania-based company announced that the U.S. Food & Drug Administration approved its application for clinical studies of MLR-1023, a first-in-class kinase...

  • Health Canada named in class action lawsuit. Eggertson, Laura // CMAJ: Canadian Medical Association Journal;7/13/2010, Vol. 182 Issue 10, p1026 

    The article reports that Health Canada was also named in the class-action lawsuits filed against GlaxoSmithKline (GSK) by the Merchant Law Group in Canada. It says that the lawsuits accuse that Health Canada fails to protect the public from the serious adverse medical effects of the medication...

  • Avandia, Risk of Congestive Heart Failure Significant Safety Risk.  // Clinical Cardiology Alert;Jul2007, Vol. 26 Issue 7, p1 

    The article reports that rosiglitazone or Avandia from GlaxoSmithKline will receive a black box warning from the U.S. Food and Drug Administration (FDA) due to concerns over heart failure associated with its use. Another drug called pioglitazone or Actos will also be subject to the warning for...

  • Selling Safety—Lessons From Muraglitazar. Brophy, James M. // JAMA: Journal of the American Medical Association;11/23/2005, Vol. 294 Issue 20, p2633 

    The article presents an editorial regarding the U.S. Food and Drug Administration's (FDA) approval of the drug muraglitazar, a dual-peroxisome proliferator-activated receptor for the treatment of type 2 diabetes. The FDA reviewed muraglitazar's efficacy and safety and recommended drug approval....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics